Status:
UNKNOWN
Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome
Lead Sponsor:
China Academy of Chinese Medical Sciences
Conditions:
Intense-exuberant Stomach Fire Syndrom
Acute Pericoronitis
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
PHASE2
Brief Summary
This clinical research focus on evaluating the effectiveness of Huanglian-Jiedu Decoction in patients with intense-exuberant stomach fire syndrome (one of the common TCM syndrome)of acute pericoroniti...
Detailed Description
Huanglian-Jiedu Decoction, as a traditional Chinese medicine formula，includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria ...
Eligibility Criteria
Inclusion
- General inclusion criteria:
- Female or male patients.
- Age: 18 - 60 years.
- Meeting the diagnostic criteria of Intense-Exuberant Stomach Fire Syndrome according to the traditional Chinese medicine.
- Patient is willing to participate voluntarily and to sign a written patient informed consent.
- Disease-specific inclusion criteria for patients with acute pericoronitis:
- 1\. Patients with clinical diagnosis of acute pericoronitis and without treatment before the study began.
- Disease-specific inclusion criteria for patients with minor recurrent aphthous stomatitis:
- Patients with clinical diagnosis of minor recurrent aphthous stomatitis(MiRAS).
- A history of MiRAS for more than 6 months and an expectation that the ulcers normally take 5 or more days to resolve without treatment.
- Ulcer occurred less than 48h hours' duration without treatment.
- Disease-specific inclusion criteria for recurrent herpes simplex labialis
- Patients with clinical diagnosis of recurrent herpes simplex labialis.
- History of recurrent herpes labialis averaging 1 or more episodes per year.
- Onset of prodrome, erythema or vesicle within 48 hours without treatment.
Exclusion
- General exclusion criteria:
- Patients with severe cardiac dysfunction on the grade of heart function over Ⅲ grade and/or liver function impairment with the value of ALT over 1.5-fold of normal value and/or renal dysfunction with the value over 133μmol/L.
- Patients who have serious, unstable, or clinically significant medical or psychological conditions, which, in the opinion of the investigator(s), would compromise the subject's participation in the study (including but not limited to arrhythmia, uncontrolled hypertension, diabetes, hepatitis, kidney failure, AIDS, cancer, etc.
- Women during pregnancy, lactation , breastfeeding or having child bearing potential without use an adequate method of birth control.
- Patients who known allergy to the study drug or the Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis ( Patients who are insufficiency of the spleen-yang according to the TCM should be exclude ).
- Patients participating in or having participated in other clinical studies in the 3 months prior to this clinical trial.
- Patients who are considered unreliable as to medication compliance or adherence to scheduled appointments.
- Disease-specific exclusion criteria for acute pericoronitis:
- Patients who smoked at least 20 cigarettes per day（heavy smokers）.
- Patients with fascial space infection of maxillofacial region or/and chronic periodontitis.
- Patients with periodontal disease in the region of the acute pericoronitis.
- Patients who had systemic administration of antibiotics within the past 4 weeks
- Disease-specific exclusion criteria for minor recurrent aphthous stomatitis(MiRAS):
- Patients with history of drug abuse within the past 6 months.
- Patients who smoked at least 20 cigarettes per day（heavy smokers）.
- Patients with ulcers as a manifestation of a systemic disease process such as ulcerative colitis, Behcet's syndrome, Reiter' s syndrome or immune deficiency.
- Patients who had systemic administration of antibiotics within the past 4 weeks or/ and had treatment with systemic steroid or immunomodulatory within 3 month before the study entry.
- Patients who had orthodontic braces or retainer that might contact with the ulcer.
- Disease-specific exclusion criteria for recurrent herpes simplex labialis:
- Patients with fever \> 38.5℃, and / or blood WBC\>11.0x109/L, and / or neutrophil \>85%.
- Patients who had systemic administration of antibiotics within the past 4 weeks or/ and had treatment with immunomodulatory within 3 month before the study entry.
Key Trial Info
Start Date :
April 4 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2018
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03469232
Start Date
April 4 2018
End Date
November 1 2018
Last Update
April 10 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Third affiliated hospital of Beijing University of traditional Chinese medicine
Beijing, Beijing Municipality, China, 100029
2
Dongfang Hospital Affiliated to Beijing University of traditional Chinese medicine
Beijing, Beijing Municipality, China, 100078
3
Affiliated Hospital to Chengdu University of traditional Chinese medicine
Chengdu, Sichuan, China, 610075